Troglitazone

What is Troglitazone

NOTE: This drug is discontinued in the US.

Troglitazone was an oral antidiabetic agent of the thiazolidinedione class, a group of drugs called ‘insulin sensitizers’.

Troglitazone specifically targeted insulin resistance and decreased both fasting and postprandial blood glucose in adult patients with type 2 diabetes mellitus (DM).

This drug was suspended from marketing in the United Kingdom in December 1997 due to concerns related to drug-induced hepatotoxicity. With the FDA approval of newer, safer thiazolidinediones (e.g., pioglitazone and rosiglitazone) in 1999, troglitazone was limited to use in type 2 DM patients who were unresponsive to other available therapies.

More than 90 cases of fulminant hepatotoxicity, including at least 63 deaths, were reported in association with the use of the drug. Due to concerns regarding drug safety and the availability of other agents in this class, the FDA and the manufacturer withdrew troglitazone from the U.S. market in March 2000.

Indications & Dosage

  • type 2 diabetes mellitus

For the treatment of type 2 diabetes mellitus in patients inadequately controlled by other available medications

Side Effects

  1. abdominal pain
  2. anorexia
  3. asthenia
  4. back pain
  5. elevated hepatic enzymes
  6. fatigue
  7. headache
  8. heart failure
  9. hepatic failure
  10. hypercholesterolemia
  11. jaundice
  12. nausea
  13. peripheral edema
  14. pharyngitis
  15. vomiting
  16. weight gain

Monitoring Parameters

  • (drug no longer available)
  • blood glucose
  • LFTs

Contraindications

  • breast-feeding
  • children
  • diabetic ketoacidosis
  • heart failure
  • hepatic disease
  • jaundice
  • polycystic ovary syndrome
  • pregnancy

Interactions

No information is available regarding drug interactions associated with Troglitazone

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top